T
CRSP icon

TRUADVICE’s CRISPR Therapeutics CRSP Stock Holding History

TRUADVICE’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$912K Buy
17,148
+2,480
+17% +$128K 0.36% 78
2023
Q2 		$734K Buy
14,668
+5,913
+68% +$336K 0.27% 96
2023
Q1 		$428K Buy
+8,755
New +$425K 0.17% 136

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRUADVICE's CRSP Position: Q3 2023 in Review

TRUADVICE increased its CRISPR Therapeutics (CRSP) stake by 17% in Q3 2023, buying an estimated $128K and bringing the position to 17,148 shares worth $912K. The position accounts for 0.36% of the portfolio, ranked #78.

TRUADVICE first reported a position in CRSP in Q1 2023 and has held it in 3 quarters since. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

  • TRUADVICE held 17,148 shares of CRISPR Therapeutics worth $912K as of Q3 2023.
  • TRUADVICE bought 2,480 CRISPR Therapeutics shares in Q3 2023, an estimated $128K.
  • CRISPR Therapeutics made up 0.36% of TRUADVICE's portfolio in Q3 2023, its #78 holding.
  • TRUADVICE first reported a position in CRISPR Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • 406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on TRUADVICE's 13F filing for Q3 2023, filed 13 Nov 2023.